Mitochondria-Targeted Therapies for Neurodegenerative Diseases

Abstract

Many neurodegenerative illnesses, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), are characterised by mitochondrial dysfunction. Neuronal degeneration is a result of alteration of mitochondrial dynamics, elevated oxidative stress, and impaired mitochondrial bioenergetics. One intriguing treatment approach to slow the progression of disease is to target the mitochondria. Recent developments in mitochondria-targeted medicine delivery, such as gene therapy, nanoparticles, small compounds, and mitochondrial transplantation techniques, are examined in this chapter. It also draws attention to the difficulties and potential uses of these tactics in healthcare settings.